Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953157 | 1.00 | HSD11B1 (1.00) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL4048422 | 1.00 | HSD11B1 (1.00) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL3946072 | 1.00 | HSD11B1 (1.00) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL4051323 | 0.96 | HSD11B1 (1.00) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL4051321 | 0.96 | HSD11B1 (1.00) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL4045123 | 0.91 | HSD11B1 (0.84) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL4045121 | 0.91 | HSD11B1 (0.84) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL14232765 | 0.89 | HSD11B1 (0.80) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL4041911 | 0.88 | HSD11B1 (0.85) | HSD11B1KCNH2CYP3A4 | |
| SCHEMBL4052236 | 0.88 | HSD11B1 (0.85) | HSD11B1KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-1703908-A4 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC (US) | 2009-07-08 | — | — | EP | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365075-B2 | Aryl sulfonamide compounds and uses related thereto | AMGEN INC. (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1703908-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | Amgen Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | AMGEN SF, LLC (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005063247-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | SULT2A1, ARSA, SULT1A1 | HSD11B1 289/4885KCNH2 2980/4885CYP3A4 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.